Boehringer Ingelheim Venture Fund and Novo Seeds have co-led the liver disease therapy developer's latest round, which included HTGF, KfW, Coparion and EIF.

Heparegenix, a Germany-based developer of therapies for acute and chronic liver diseases, raised €9m ($9.4m) in a series A round yesterday co-led by pharmaceutical firms Boehringer Ingelheim and Novo.

The corporates invested through subsidiaries Boehringer Ingelheim Venture Fund and Novo Seeds and were joined by public-private partnership High-Tech Gruenderfonds (HTGF), investment fund Coparion, development bank KfW and European Investment Fund (EIF), part of EU-owned financial institution European Investment Bank.

Founded in 2015, Heparegenix is aiming to treat acute and chronic…